Related Experiment Videos
[Determination of drug posology in pediatrics]
Insights
Determining pediatric drug dosage requires toxicological data, adapted formulations, and pharmacokinetic studies to avoid empirical use. Incentives like public funding and patent extensions can aid pediatric drug development.
Area of Science:
- Pharmacology and Toxicology
- Pediatric Drug Development
Context:
- Establishing safe and effective pediatric drug dosages is crucial to prevent empirical use.
- Paediatric drug development faces challenges including ethical considerations and high costs.
Purpose:
- To outline the essential steps and data required for determining pediatric drug dosages.
- To discuss the drawbacks and propose incentives for pediatric drug development.
Summary:
- Paediatric drug dosage determination necessitates toxicological evaluation, growth assessment, adapted pharmaceutical forms, and pharmacokinetic data.
- Preliminary doses are extrapolated from adult data, refined through dose-effect studies, and finalized using age-specific pharmacokinetic data.
- Challenges include obtaining parental consent and the overall cost of studies.
Impact:
- Ensuring appropriate and safe medication for pediatric populations.
- Facilitating the development of new drugs and indications for children.
- Highlighting the need for supportive measures to advance pediatric pharmacotherapy.
Abstract:
The dosage of drugs which might be used in children must be determined to avoid empirical use, even when no application has been submitted for a paediatric licence. Toxicological evaluation and assessment of the effects on growth, an adapted pharmaceutical form and paediatric pharmacokinetic and adult clinical data are essential before conducting trials designed to determine the paediatric dosage. The dose used during preliminary studies is extrapolated from the adult dose expressed in relation to weight, tested in a dose-effect study, and then more accurately defined on the basis of pharmacokinetic data in different age groups. Obtaining consent from both parents for studies whose direct benefit is not always obvious, as well as the global cost of these studies, constitute drawbacks to paediatric drug development. Incentives to determine a paediatric dosage could consist of public participation in funding, prolongation of the patent, and granting an advantageous price for a specifically paediatric pharmaceutical form or indication.